It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
N6-methyladenosine (m6A) modification is an important mechanism in miRNA processing and maturation, but the role of its aberrant regulation in human diseases remained unclear. Here, we demonstrate that oncogenic primary microRNA-25 (miR-25) in pancreatic duct epithelial cells can be excessively maturated by cigarette smoke condensate (CSC) via enhanced m6A modification that is mediated by NF-κB associated protein (NKAP). This modification is catalyzed by overexpressed methyltransferase-like 3 (METTL3) due to hypomethylation of the METTL3 promoter also caused by CSC. Mature miR-25, miR-25-3p, suppresses PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2), resulting in the activation of oncogenic AKT-p70S6K signaling, which provokes malignant phenotypes of pancreatic cancer cells. High levels of miR-25-3p are detected in smokers and in pancreatic cancers tissues that are correlated with poor prognosis of pancreatic cancer patients. These results collectively indicate that cigarette smoke-induced miR-25-3p excessive maturation via m6A modification promotes the development and progression of pancreatic cancer.
Cigarette smoke induces microRNA dysregulation in cancers. Here, the authors show that cigarette smoke promotes the maturation of oncogenic primary miR-25 due to METTL3 hypomethylation, and mature miR-25 suppresses PH domain leucine-rich repeat protein phosphatase 2, resulting in oncogenic AKT activation in pancreatic cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China (GRID:grid.488530.2) (ISNI:0000 0004 1803 6191)
2 Sun Yat-sen University Cancer Center, Department of Pathology, Guangzhou, China (GRID:grid.488530.2) (ISNI:0000 0004 1803 6191)
3 Sun Yat-sen University, Department of Pancreaticobiliary Surgery, Sun Yat-sen Memorial Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
4 Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Beijing, China (GRID:grid.413106.1) (ISNI:0000 0000 9889 6335); Chinese Academy of Medical Sciences and Peking Union Medical College, CAMS Key Laboratory of Genetics and Genomic Biology, Beijing, China (GRID:grid.413106.1) (ISNI:0000 0000 9889 6335)
5 Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Abdominal Surgery, National Cancer Center/National Clinical Research Center/Cancer Hospital, Beijing, China (GRID:grid.413106.1) (ISNI:0000 0000 9889 6335)
6 Sun Yat-sen University, Department of Pancreaticobiliary Surgery, Sun Yat-sen Memorial Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
7 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China (GRID:grid.488530.2) (ISNI:0000 0004 1803 6191); Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Beijing, China (GRID:grid.413106.1) (ISNI:0000 0000 9889 6335); Chinese Academy of Medical Sciences and Peking Union Medical College, CAMS Key Laboratory of Genetics and Genomic Biology, Beijing, China (GRID:grid.413106.1) (ISNI:0000 0000 9889 6335)